<?xml version='1.0' encoding='utf-8'?>
<document id="20524153"><sentence text="Isavuconazole: a comprehensive review of spectrum of activity of a new triazole."><entity charOffset="0-13" id="DDI-PubMed.20524153.s1.e0" text="Isavuconazole" /><entity charOffset="71-79" id="DDI-PubMed.20524153.s1.e1" text="triazole" /><pair ddi="false" e1="DDI-PubMed.20524153.s1.e0" e2="DDI-PubMed.20524153.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20524153.s1.e0" e2="DDI-PubMed.20524153.s1.e1" /></sentence><sentence text="Isavuconazole is a new triazole currently undergoing phase III clinical trials"><entity charOffset="0-13" id="DDI-PubMed.20524153.s2.e0" text="Isavuconazole" /><entity charOffset="23-31" id="DDI-PubMed.20524153.s2.e1" text="triazole" /><pair ddi="false" e1="DDI-PubMed.20524153.s2.e0" e2="DDI-PubMed.20524153.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20524153.s2.e0" e2="DDI-PubMed.20524153.s2.e1" /></sentence><sentence text=" This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp" /><sentence text=", Fusarium spp" /><sentence text=", Scedosporium spp" /><sentence text=", Candida spp" /><sentence text=", the Zygomycetes and Cryptococcus spp" /><sentence text=" Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum"><entity charOffset="12-24" id="DDI-PubMed.20524153.s8.e0" text="voriconazole" /></sentence><sentence text=" In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis" /><sentence text=" Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents" /><sentence text=" This review summarizes existing data that has been either published or presented at international symposia" /><sentence text="" /></document>